{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:44:11Z","timestamp":1792514651382,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004917","name":"Doosan Yonkang Foundation","doi-asserted-by":"publisher","award":["30-2012-0100"],"award-info":[{"award-number":["30-2012-0100"]}],"id":[{"id":"10.13039\/501100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["05-2009-0030"],"award-info":[{"award-number":["05-2009-0030"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peritoneal recurrence (PR) is a major relapse pattern of colorectal cancer (CRC). We investigated whether peritoneal immune cytokines can predict PR. Cytokine concentrations of peritoneal fluid from CRC patients were measured. Patients were grouped according to peritoneal cancer burden (PCB): no tumor cells (\u2264\u2009pT3), microscopic tumor cells (pT4), or gross tumors (M1c). Cytokine concentrations were compared among the three groups and the associations of those in pT4 patients with and without postoperative PR were assessed. Of the ten cytokines assayed, IL6, IL10, and TGFB1 increased with progression of PCB. Among these, IL10 was a marker of PR in pT4 (N\u2009=\u200961) patients based on ROC curve (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). The IL10 cut-off value (14\u00a0pg\/mL) divided patients into groups with a low (7%, 2 of 29 patients) or high (45%, 16 of 32 patients) 5-year PR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Multivariable analysis identified high IL10 levels as the independent risk factor for PR. Separation of patients into training and test sets to evaluate the performance of IL10 cut-off model validated this cytokine as a risk factor for PR. Peritoneal IL10 is a prognostic marker of PR in pT4 CRC. Further research is necessary to identify immune response of intraperitoneal CRC growth.<\/jats:p>","DOI":"10.1038\/s41598-021-88653-2","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:04:55Z","timestamp":1619604295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interleukin 10 level in the peritoneal cavity is a prognostic marker for peritoneal recurrence of T4 colorectal cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Seung-Yong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong Geon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Seong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chul","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"88653_CR1","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1007\/BF02253499","volume":"35","author":"A Yamaguchim","year":"1992","unstructured":"Yamaguchim, A. et al. Intraperitoneal hyperthermic treatment for peritoneal dissemination of colorectal cancers. Dis. Colon Rectum. 35, 964\u2013968 (1992).","journal-title":"Dis. Colon Rectum."},{"key":"88653_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1245\/s10434-012-2473-5","volume":"20","author":"C Honore","year":"2013","unstructured":"Honore, C., Goere, D., Souadka, A., Dumont, F. & Eliasm, D. Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: A systematic review. Ann. Surg. Oncol. 20, 183\u2013192 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"88653_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/BF02050360","volume":"34","author":"JT Brodsky","year":"1991","unstructured":"Brodsky, J. T. & Cohen, A. M. Peritoneal seeding following potentially curative resection of colonic carcinoma: Implications for adjuvant therapy. Dis. Colon Rectum. 34, 723\u2013727 (1991).","journal-title":"Dis. Colon Rectum."},{"key":"88653_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/bjc.2014.419","volume":"111","author":"R Mirnezami","year":"2014","unstructured":"Mirnezami, R. et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br. J. Cancer 111, 1500\u20131508 (2014).","journal-title":"Br. J. Cancer"},{"key":"88653_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3393\/ac.2014.30.6.266","volume":"30","author":"SJ Bae","year":"2014","unstructured":"Bae, S. J. et al. Role of peritoneal lavage cytology and prediction of prognosis and peritoneal recurrence after curative surgery for colorectal cancer. Ann. Coloproctol. 30, 266\u2013273 (2014).","journal-title":"Ann. Coloproctol."},{"key":"88653_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jso.23052","volume":"106","author":"MS del Rossi","year":"2012","unstructured":"del Rossi, M. S. et al. Free peritoneal tumor cells detection in gastric and colorectal cancer patients. J. Surg. Oncol. 106, 17\u201323 (2012).","journal-title":"J. Surg. Oncol."},{"key":"88653_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00595-014-1066-2","volume":"45","author":"T Nishikawa","year":"2015","unstructured":"Nishikawa, T. et al. Incidence and prognostic significance of positive peritoneal lavage in colorectal cancer. Surg. Today 45, 1073\u20131081 (2015).","journal-title":"Surg. Today"},{"issue":"6382","key":"88653_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350\u20131355 (2018).","journal-title":"Science"},{"issue":"5795","key":"88653_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960\u20131964 (2006).","journal-title":"Science"},{"issue":"10135","key":"88653_CR10","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","volume":"391","author":"F Pag\u00e8s","year":"2018","unstructured":"Pag\u00e8s, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet 391(10135), 2128\u20132139 (2018).","journal-title":"Lancet"},{"issue":"26","key":"88653_CR11","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"88653_CR12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion. Science 331, 1565\u20131570 (2011).","journal-title":"Science"},{"key":"88653_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-013-3461-0","volume":"21","author":"HC van Santvoort","year":"2014","unstructured":"van Santvoort, H. C. et al. Peritoneal carcinomatosis in t4 colorectal cancer: Occurrence and risk factors. Ann. Surg. Oncol. 21, 1686\u20131691 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"88653_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman, J. et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg. 99, 699\u2013705 (2012).","journal-title":"Br. J. Surg."},{"key":"88653_CR15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41416-019-0442-5","volume":"120","author":"H Nagata","year":"2019","unstructured":"Nagata, H. et al. LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer. Br. J. Cancer 120, 996\u20131002 (2019).","journal-title":"Br. J. Cancer"},{"issue":"4","key":"88653_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21(4), 687\u2013692 (2015).","journal-title":"Clin. Cancer Res."},{"key":"88653_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","volume":"5","author":"A Corthay","year":"2014","unstructured":"Corthay, A. Does the immune system naturally protect against cancer?. Front. Immunol. 5, 197 (2014).","journal-title":"Front. Immunol."},{"key":"88653_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2008.00706.x","volume":"226","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Zhang, X. Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 226, 205\u2013218 (2008).","journal-title":"Immunol. Rev."},{"key":"88653_CR19","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.163.11.6251","volume":"163","author":"AE Loercher","year":"1999","unstructured":"Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D. & Freedman, R. S. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J. Immunol. 163, 6251\u20136260 (1999).","journal-title":"J. Immunol."},{"key":"88653_CR20","first-page":"1943","volume":"4","author":"RJ O'Hara","year":"1998","unstructured":"O\u2019Hara, R. J. et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin. Cancer Res. 4, 1943\u20131948 (1998).","journal-title":"Clin. Cancer Res."},{"key":"88653_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/clim.2001.5163","volume":"102","author":"G Galizia","year":"2002","unstructured":"Galizia, G. et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102, 169\u2013178 (2002).","journal-title":"Clin. Immunol."},{"key":"88653_CR22","first-page":"2678","volume":"9","author":"L Giacomelli","year":"2003","unstructured":"Giacomelli, L. et al. Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clin. Cancer Res. 9, 2678\u20132682 (2003).","journal-title":"Clin. Cancer Res."},{"key":"88653_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/1043-4666(92)90082-3","volume":"4","author":"WH Gotlieb","year":"1992","unstructured":"Gotlieb, W. H. et al. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4, 385\u2013390 (1992).","journal-title":"Cytokine"},{"key":"88653_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00002371-199901000-00004","volume":"22","author":"D Piancatelli","year":"1999","unstructured":"Piancatelli, D., Romano, P., Sebastiani, P., Adorno, D. & Casciani, C. U. Local expression of cytokines in human colorectal carcinoma: Evidence of specific interleukin-6 gene expression. J. Immunother. 22, 25\u201332 (1999).","journal-title":"J. Immunother."},{"key":"88653_CR25","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3","volume":"85","author":"T Kinoshita","year":"1999","unstructured":"Kinoshita, T., Ito, H. & Miki, C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85, 2526\u20132631 (1999).","journal-title":"Cancer"},{"key":"88653_CR26","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.ejca.2005.07.014","volume":"41","author":"W Brozek","year":"2005","unstructured":"Brozek, W. et al. Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: Relevance for tumour progression. Eur. J. Cancer 41, 2347\u20132354 (2005).","journal-title":"Eur. J. Cancer"},{"key":"88653_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904\u2013910 (2012).","journal-title":"Cancer Treat. Rev."},{"key":"88653_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-016-9791-0","volume":"33","author":"N Sluiter","year":"2016","unstructured":"Sluiter, N. et al. Adhesion molecules in peritoneal dissemination: Function, prognostic relevance and therapeutic options. Clin. Exp. Metastasis 33, 401\u2013416 (2016).","journal-title":"Clin. Exp. Metastasis"},{"key":"88653_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 80, 27\u201338 (1993).","journal-title":"Biometrika"},{"key":"88653_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch, P. M. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515\u2013526 (1994).","journal-title":"Biometrika"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88653-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T21:58:47Z","timestamp":1698962327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88653"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88653-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9212"}}